Website Information
    Web Site Information :.   Site Info    Whois    Traceroute    RBL Check  

Enter Web Site URL Address:
 

elinogrel.net: Portola Pharmaceuticals, Inc. Discovering and developing novel therapeutics.
Portola Pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases Portolas two most advanced programs are in Phase II clinical trials: 1) betrixaban, an oral, once-daily Factor Xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (SPAF) and for prevention of venous thromboembolism (VTE) in various patient populations, and 2) elinogrel, a direct-acting, reversible oral and i.v. ADP receptor antagonist initially being developed for patients with acute coronary syndrome (ACS).  
 
 

Portola Pharmaceuticals, Inc. Discovering and developing novel therapeutics.

Description: Portola Pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases Portolas two most advanced programs are in Phase II clinical trials: 1) betrixaban, an oral, once-daily Factor Xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (SPAF) and for prevention of venous thromboembolism (VTE) in various patient populations, and 2) elinogrel, a direct-acting, reversible oral and i.v. ADP receptor antagonist initially being developed for patients with acute coronary syndrome (ACS).

Keywords: biopharmaceutical company, innovative drugs, treatment of cardiovascular diseases, inflammatory diseases, betrixaban, Factor Xa inhibitor, stroke prevention, atrial fibrillation, prevention of venous thromboembolism, elinogrel, oral and i.v. ADP receptor antagonist, acute coronary syndrome, antithrombotic, thrombosis, inflammatory diseases

Tags: elinogrel, portola, pharmaceuticals, profiles, developing, therapeutics, novel, discovering, inhibitor, overview, thrombosis, company, prt, syk, programs, jak, oral, betrixaban, diseases, prevention, news, product, pdf, therapeutic, pipeline, board, publications, newsroom, areas, inflammatory, inflammation, trials, clinical, dual, development, specific, antagonist, stroke, atrial, fibrillation,

Elinogrel.net

Content Revalency: Title: 50.00%   Description: 60.00%   Keywords: 78.12%  |  Document size: 9,196 bytes
More info: Whois - Trace Route - RBL Check
 
ELINOGREL.NET - Site Location
Country/Flag US United States
City/Region/Zip Code Gilbert, AZ, 85233
Organization GoDaddy.com, LLC
Internet Service Provider GoDaddy.com, LLC
 
ELINOGREL.NET - Domain Information
Domain ELINOGREL.NET   [ Traceroute  RBL/DNSBL lookup ]
Registrar GODADDY.COM, LLC GoDaddy.com, LLC
Registrar URL http://www.godaddy.com
Whois server whois.godaddy.com
Created 14-Jan-2009
Updated 29-Mar-2016
Expires 21-Jan-2017
Time Left 0 days 0 hours 0 minutes
Status clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited clientRenewProhibited https://icann.org/epp#clientRenewProhibited clientTransferProhibited https://icann.org/epp#clientTransferProhibited clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited
DNS servers NS23.DOMAINCONTROL.COM   64.202.165.107
NS24.DOMAINCONTROL.COM   208.109.255.12
 
ELINOGREL.NET - DNS Information
IP Address 64.202.189.170 ~ Whois - Trace Route - RBL Check
Domain Name Servers ns23.domaincontrol.com   97.74.101.12
ns24.domaincontrol.com   173.201.69.12
Mail Exchange smtp.secureserver.net   92.204.80.0
mailstore1.secureserver.net   92.204.80.3
 
Site Response Header
Response HTTP/1.1 200 OK
Server Microsoft-IIS/6.0
Date Mon, 11 Apr 2011 05:29:23 GMT
Content-Type text/html; charset=utf-8


  IP Index    TLD Index    Domain Index    Site Index New   Copyright © 2025 Cybernet Quest.